Skip to main content

Table 2 Metastatic disease locations and median lesion SUVmax for each patient

From: Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study

Patient # Tumor type Disease locations PSMA median SUVmax (range) FDG median SUVmax (range) Neck MRI findings Liver SUVmax PSMA > liver + No FDG/PSMA discordance?
1 PTC B 9.0 (1.0–10.1) 21.1 (4.1–28.4) Post-tx, bone mets (P,F) 7.2 Yes
2 HCC B, ST 11.0 (3.4–27.8) 11.6 (4.7–31.3) Post-tx, bone mets (F) 13.2 Yes
3 PDPTC ST 4.5 (1.9–6.2) 5.3 (4.1–10.3) Post-tx (non-avid) 5.6 Yes
4 ATC ST, TB 3.3 (1.6–6.0) 14.3 (4.2–19.1) Post-tx, “treated” residual TB tissue (P,F) 9.5 No
5 FTC B 15.0 (15.0–15.0) 3.5 (3.5–3.5) Post-tx (non-avid) 6.5 Yes
6 PDPTC LN, ST, TB 8.5 (4.3–12.6) 4.1 (2.6–5.6) Post-tx (P,F) 10.2 Yes
7 PTC ST 2.7 (2.7–2.7) 17.0 (17.0–17.0) Post-tx (non-avid) 9.2 No
8 ATC TB 6.0 (5.7–6.3) 14.1 (13.8–14.3) Post-tx, TB soft tissue (P,F) 5.7 Yes
9 PTC LN 2.5 (2.0–11.4) 5.9 (5.3–6.9) Post-tx, decreasing cervical LN (F) 7.1 Yes
10 FTC B 13.8 (9.2–18.3) 8.0 (7.4–8.7) Post-tx (non-avid) 5.4 Yes
11 HCC ST 2.8 (2.5–3.1) 4.3 (3.9–4.7) Post-tx (non-avid) 13.9 No
  1. B bones, ST soft tissues, TB thyroid bed, LN lymph nodes, Post-tx post-treatment changes (thyroidectomy, scarring, and/or lymph node dissection). The last column refers to PSMA RLT eligibility criteria used in a recent phase 2 trial of PSMA RLT in prostate cancer [21]. Reasons for lack of eligibility: patient 4—FDG avid lung metastases not seen on PSMA; patient 8—FDG avid lung metastases with minimal uptake on PSMA; patient 12—FDG avid lung metastases not seen on PSMA